University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
Leuk Lymphoma. 2012 Jan;53(1):50-6. doi: 10.3109/10428194.2011.616611. Epub 2011 Oct 24.
Elevated serum CD44, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) have been linked to poor prognosis in aggressive lymphomas, but their utility in low grade lymphomas remains undefined. We evaluated serum CD44, VCAM-1 and ICAM-1 levels in 100 patients with newly diagnosed indolent NHL. The median pre-treatment values of the markers were as follows: CD44 540 ng/mL (range 156-1201), ICAM-1 311 ng/mL (range 102-1222) and VCAM-1 1165 ng/mL (range 248-4779). On univariate analysis, elevated sCD44, sICAM-1 and sVCAM-1 were significantly associated with worse overall (OS) and progression-free survival (PFS). In a subset analysis of patients with stage IV disease, the effects of sCD44 and sICAM-1 on OS persisted (p<0.05), as did the effect of sCD44 on PFS (p<0.01). In a multivariate analysis that included conventional prognostic factors and the Follicular Lymphoma International Prognostic Index (FLIPI) model, sICAM-1 demonstrated prognostic value for OS and PFS. We conclude that serum CD44, ICAM-1 and VCAM-1 can potentially be prognostic in patients with indolent NHL. Though the FLIPI model remains the gold standard for prognosis, these quantitative serologic markers may be useful as adjunct tools in assessing disease risk.
血清 CD44、细胞间黏附分子-1（ICAM-1）和血管细胞黏附分子-1（VCAM-1）水平升高与侵袭性淋巴瘤的预后不良相关，但它们在低级别淋巴瘤中的应用仍未确定。我们评估了 100 例新诊断的惰性 NHL 患者的血清 CD44、VCAM-1 和 ICAM-1 水平。标志物的中位治疗前值如下：CD44 540ng/mL（范围 156-1201），ICAM-1 311ng/mL（范围 102-1222）和 VCAM-1 1165ng/mL（范围 248-4779）。在单因素分析中，升高的 sCD44、sICAM-1 和 sVCAM-1 与总生存期（OS）和无进展生存期（PFS）显著相关。在 IV 期疾病患者的亚组分析中，sCD44 和 sICAM-1 对 OS 的影响仍然存在（p<0.05），sCD44 对 PFS 的影响也是如此（p<0.01）。在包括常规预后因素和滤泡性淋巴瘤国际预后指数（FLIPI）模型的多因素分析中，sICAM-1 对 OS 和 PFS 具有预后价值。我们得出结论，血清 CD44、ICAM-1 和 VCAM-1 可能对惰性 NHL 患者具有预后价值。虽然 FLIPI 模型仍然是预后的金标准，但这些定量血清标志物可能是评估疾病风险的有用辅助工具。
